@article{oai:niigata-u.repo.nii.ac.jp:00018894,
 author = {菊池, 透 and 橋本, 尚士 and 川崎, 琢也 and 内山, 聖},
 issue = {11},
 journal = {新潟医学会雑誌, 新潟医学会雑誌},
 month = {Nov},
 note = {The effects of growth hormone (GH) on bone metabolism were studied in 8 GH-deficient children. Biochemical markers for bone metabolism, such as osteocalcin, alkakine phoshatase (ALP), insulin like growth factor-I (IGF-I), calcium, phosphate, renal tubular reabsorption of phosphate (%TRP), vaitamin D_3, parathyroid hormone (PTH) and calcitonin, and bone mineral density (BMD) were measured before and 1, 2, 3, 6, 9, 12 months after treatment with GH. BMD was determined by dual energy X-ray absorptiometry at 2nd～4th lumbar spine by using a model QDR 1,000 (Hologic Corp., Waltham, Massachusetts). All children had significant increment of body height (BH) SD score, height velocity and height velocity SD score. We compared these makers and BMD of pretreatment with those of posttreatment. The following results were obtained. 1) Significant increment of osteocalcin, ALP and IGF-I serum level were found. 2) Serum levels of Calcium and phosphate, and %TRP showed a tendency to increase. 3) Serum level of 1,25-(OH)_2 vaitamin D_3 showed a tendency to increase. However serum levels of 25-(OH) vaitamin D_3 and 24,25-(OH)_2 vaitamin D_3 showed a tendency to decrease. 4) No significant chages in PTH C-terminal and calcitonin levels were found. 5) A significant increment of BMD was found. However no significant variation of BMD/BH was found. Bone metabolism is regulated by numerous hormones and local growth factors. Our findings suggest that the treatment with GH may affect this network of bone metabolism and stimulat bone turnover, especially bone formation.},
 pages = {815--819},
 title = {3)成長ホルモン療法における骨代謝の検討(シンポジウム 骨粗鬆症の病態・治療・予防, 第493回新潟医学会)},
 volume = {108},
 year = {1994}
}